CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-04 | Hamilton James C Chief Discovery/Trans Medicine | Grant or award 10b5-1 | +100,000 | 304,851 | ||
| 2025-01-04 | O'Brien Patrick COO and General Counsel | Grant or award 10b5-1 | +100,000 | 564,385 | ||
| 2025-01-04 | Myszkowski Kenneth Allen Chief Financial Officer | Grant or award 10b5-1 | +100,000 | 500,600 | ||
| 2025-01-02 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −11,520 | $19.05 | $219K | 3,764,252 |
| 2024-12-27 | OLUKOTUN ADEOYE Y Director | Sale 10b5-1 | −2,850 | $20.00 | $57K | 36,740 |
| 2024-12-23 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −12,563 | $19.59 | $246K | 3,775,772 |
| 2024-12-18 | Vakiener Victoria Director | Grant or award | +16,733 | $22.99 | $385K | 37,944 |
| 2024-12-18 | OLUKOTUN ADEOYE Y Director | Grant or award | +16,733 | $22.99 | $385K | 39,590 |
| 2024-12-18 | Waddill William D. Director | Grant or award | +16,733 | $22.99 | $385K | 57,111 |
| 2024-12-18 | Ferrari Mauro Director | Grant or award | +16,733 | $22.99 | $385K | 77,514 |
| 2024-12-18 | PERRY MICHAEL S Director | Grant or award | +16,733 | $22.99 | $385K | 131,490 |
| 2024-12-18 | Lu Hongbo Director | Grant or award | +16,733 | $22.99 | $385K | 47,163 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −12,653 | $20.52 | $260K | 3,702,394 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −8,260 | $21.74 | $180K | 3,694,134 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −5,799 | $22.12 | $128K | 3,688,335 |
| 2024-12-18 | Anzalone Christopher Richard Chief Executive Officer | Grant or award 10b5-1 | +100,000 | 3,788,335 | ||
| 2024-12-17 | Waddill William D. Director | Sale 10b5-1 | −3,747 | $22.04 | $83K | 40,378 |
| 2024-12-17 | GIVEN DOUGLAS B Director | Sale 10b5-1 | −547 | $22.04 | $12K | 124,167 |
| 2024-12-16 | Waddill William D. Director | Sale 10b5-1 | −3,748 | $21.90 | $82K | 44,125 |
| 2024-12-16 | GIVEN DOUGLAS B Director | Sale 10b5-1 | −5,000 | $21.90 | $110K | 124,714 |
Page 7 of 28 · 542 trades